Skip to main content
Premium Trial:

Request an Annual Quote

FDA Warns Beckman Coulter of Violations at Miami Facility

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has issued a warning letter to Beckman Coulter citing issues it identified at the company's Miami facility.

In a letter dated Nov. 1 and posted this week on FDA's website, the agency said that it had found that Class I and II in vitro diagnostic products manufactured at the site were "adulterated … and not in conformity with the Current Good Manufacturing Practice requirements" as defined by federal regulations.

Among the myriad of violations noted by FDA investigators was a failure to create and maintain "adequate procedures for implementing corrective and preventive action;" failure to establish and maintain adequate customer complaint procedures; and failure to establish and maintain proper personnel training procedures.

The agency also determined that Beckman Coulter's DxH, LH , HmX, and Diff series of hematology analyzers, as well as reagents used on the analyzers, were misbranded "in that your firm failed or refused to furnish material or information" related to the devices.

In addition, FDA said that the company had failed to report to the agency within a 30-day timeframe information that a device marketed by Beckman Coulter had malfunctioned "and would be likely to cause or contribute to death or serious injury if the malfunction were to recur."

FDA's findings were based on inspections done at the Miami facility between Feb. 28 and June 2. Beckman Coulter President and CEO J. Robert Hurley responded to FDA's concerns in July and August, but the adequacy of his responses in many instances could not be determined due to a lack of documentation, proof of implementation of required procedures, or other factors, FDA said.

FDA has asked Beckman Coulter to respond to its concerns within 15 days of receiving the warning letter with information about specific steps it has taken to address the violations and how it plans to prevent such violations, or similar ones, from occurring again.

It is unclear if Beckman Coulter has done so. The company did not respond to a request for comment.

In August FDA sent a warning letter to Beckman Coulter about violations it found at its facility in Brea, Calif., in connection with its AccuTnl troponin test kits that run on its UniCel DxI immunoassay system.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.